Secukinumab und Ixekizumab bei Psoriasis: Beträchtlicher Zusatznutzen für bestimmte Patienten
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Deutsch
- Erschienen in
-
Secukinumab und Ixekizumab bei Psoriasis: Beträchtlicher Zusatznutzen für bestimmte Patienten ; volume:42 ; number:04 ; year:2017 ; pages:268-269
Aktuelle Rheumatologie ; 42, Heft 04 (2017), 268-269
- DOI
-
10.1055/s-0043-112978
- URN
-
urn:nbn:de:101:1-2019041114585643972239
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Ähnliche Objekte (12)
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Ixekizumab bei Psoriasis-Arthritis & axialer Spondyloarthritis : umfassende Daten zu Ixekizumab: schnelle und kontinuierliche Wirksamkeit
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Ixekizumab: an alternative for HIV-positive psoriasis patients
Ixekizumab (Plaque Psoriasis) : Nutzenbewertung gemäß § 35a SGB V
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Ixekizumab bei Psoriasis-Arthritis & axialer Spondyloarthritis : umfassende Daten zu Ixekizumab: schnelle und kontinuierliche Wirksamkeit
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Ixekizumab: an alternative for HIV-positive psoriasis patients
Ixekizumab (Plaque Psoriasis) : Nutzenbewertung gemäß § 35a SGB V
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Ixekizumab bei Psoriasis-Arthritis & axialer Spondyloarthritis : umfassende Daten zu Ixekizumab: schnelle und kontinuierliche Wirksamkeit
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Ixekizumab: an alternative for HIV-positive psoriasis patients